About this medicine
Product information is provided to support understanding and conversations with your care team. Follow the approved leaflet and your prescriber’s instructions.
Content migrated from the company website; pending clinical review before final publication.
Dosage forms
Oral capsules (140, 280, 420 and 560 mg)
Drug class
Tyrosine kinase inhibitor; Bruton’s tyrosine kinase (BTK) inhibitor
Administration
Take capsules with a glass of water at consistent times each day. Swallow capsules whole; do not chew, crush or break them. They may be taken with or without food. Adequate hydration during treatment is recommended. When combined with rituximab, ibrutinib should be taken before rituximab on the same day.
Uses
• Treatment-resistant chronic graft-versus-host disease
• Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)
• Waldenström macroglobulinemia
Competitive advantages
As a BTK inhibitor, ibrutinib represents a milestone in the treatment of chronic lymphocytic leukemia (CLL) and other B-cell disorders. By blocking signaling in malignant B cells, it inhibits their growth and proliferation and consequently helps improve patient survival. Ibrutinib is particularly effective in patients with mutations associated with resistance to chemotherapy and is used as first-line treatment in CLL. Its sustained effectiveness and ability to reduce the risk of relapse make it an ideal choice in treating these diseases.
Original company product page ↗